Journal: Cell Discovery

Article Title: Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

doi: 10.1038/s41421-022-00449-4

Figure Lengend Snippet: a Binding profiles of F61 and D2 to different spike proteins (WIV04-S1, WIV04-RBD, WIV04-NTD, Delta-S1, Delta-RBD and Omicron-RBD) were determined by ELISA. F61 and D2 bound to diverse RBD and S1 fragments but not WIV04-NTD with EC 50 values less than 4.5 ng/mL, indicating that they were both RBD-specific antibodies. Experiments were performed in duplicate, n = 2. Data are represented as means ± SD (upper panel) and means (down panel). b Binding kinetics ( K D ) of the monoclonal antibodies (mAbs) with Delta-RBD, Omicron-RBD (BA.1 and BA.2) were measured by SPR. c mAbs blocked SARS-CoV-2 WT-RBD binding to ACE2 measured by FACS. The X-axis represented the fluorescence intensity of human antibodies labeled by FITC, and the Y-axis represented the fluorescence intensity of RBD-mFc labeled by Taxes Red. Percentages of cells that scored negative, single positive, or double positive are shown in each quadrant.

Article Snippet: ELISA plates were coated with SARS-CoV-2 protein including WT-S1, WT-NTD, WT-RBD, Delta-S1, Delta-RBD and Omicron-RBD (Sino Biological, China) at 4 °C overnight.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Fluorescence, Labeling

Journal: Cell Discovery

Article Title: Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

doi: 10.1038/s41421-022-00449-4

Figure Lengend Snippet: a Overall structure of SARS-CoV-2 S in complex with F61 Fab. The tilt angle of RBD is defined by the angle between the long axis of RBD (red line) and its projection on the horizontal plane (black ellipse). Angle between them is indicated. SARS-CoV-2 RBD is colored in cyan, other domains in gray, heavy chain of F61 in magenta and light chain of F61 in violet. Related to Supplementary Fig. . b Overall structure of SARS-CoV-2 S in complex with D2 Fab. The tilt angle of RBD is defined by the angle between the long axis of RBD (red line) and its projection on the horizontal plane (black ellipse). Angle between them is indicated. SARS-CoV-2 RBD is colored in cyan, other domains in gray, heavy chain of D2 in orange and light chain of D2 in light orange. Related to Supplementary Fig. . c Overall structures of SARS-CoV-2 Omicron S in complex with F61 Fab and D2 Fab. Color schemes are the same as a and b . Related to Supplementary Fig. . d Structural superposition of RBD-fab and RBD-ACE2 (PDB ID: 6M0J) structures and the footprints of F61, D2 and ACE2 on the RBD, and structure of Omicron-RBD-F61-D2 with footprints of F61 and D2 on the RBD. ACE2 is colored in blue. The footprints of F61, D2 and ACE2 are represented as magenta, orange and blue, respectively. Other color schemes are the same as a and b .

Article Snippet: ELISA plates were coated with SARS-CoV-2 protein including WT-S1, WT-NTD, WT-RBD, Delta-S1, Delta-RBD and Omicron-RBD (Sino Biological, China) at 4 °C overnight.

Techniques:

Journal: Scientific Reports

Article Title: Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection

doi: 10.1038/srep45552

Figure Lengend Snippet: ( A ) Four murine anti-EBOV mAbs, M001, M401, M318, and M501, were injected to evaluate their prevention efficacies (upper) and treatment efficacies (lower). The mAbs were injected at 3 days or 4 h before the inoculation of pHIV–ZGP–Fluc to determine their preventive efficacies, and at 12 h or 3 days after viral inoculation to determine their treatment efficacies. Photon flux was measured at 4 dpi. The first column shows the control pHIV–ZGP–Fluc-infected BALB/c mice that did not receive any mAb treatment. ( B – C ) Preventive efficacy ( B ) and treatment efficacy ( C ) were detected as the total photon flux in pHIV–ZGP–Fluc-infected mice treated with various mAbs compared with that in similarly infected mice without mAb treatment (first column). * p < 0.05; ** p < 0.01. ( D – I ) ELISA binding curves for recombinant GP proteins, including recombinant GP ( D ) and its receptor-binding domain ( E ) from EBOV strain H.sapiens-wt/GIN/2014/Kissidougou-C15 and recombinant GP ( F ), receptor-binding domain ( G ), GP2 ( H ), and GP1 ( I ) from EBOV strain Mayinga 1976.

Article Snippet: A 6-week-old female BALB/c mouse was immunized by an IP injection with 5 μg of a recombinant GP1 protein (40442-V08B) from EBOV (strainH.sapiens-wt/GIN/2014/Kissidougou- C15) and recombinant GP protein (40304-V08B1) from subtype Zaire, strain Mayinga 1976 (Sinobiological Inc., Beijing, China).

Techniques: Injection, Infection, Enzyme-linked Immunosorbent Assay, Binding Assay, Recombinant

Journal: Nature Communications

Article Title: Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1

doi: 10.1038/s41467-023-44504-4

Figure Lengend Snippet: A A total of 19 compounds from a library containing 974 plant-sourced small molecules were tested at 1 μM for antiviral activity to EBOV, HIV-1, and VSV using HIV-1 Luc-reporter pseudoviruses. EBOV-GP (red)- and VSV-G (blue)-mediated infection were conducted in Vero-E6 cells, and HIV-1 Env (green)-mediated infection was done in TZM-bI cells. Five compounds specifically targeting EBOV are circled. Viral infection was shown as intracellular luciferase activity. RLU, relative light unit. B The chemical structures of six compounds are shown. C The anti-EBOV activity of Toremifene citrate (Tor), Tamoxifen citrate (Tam), and Tubeimosides (Tubs) I/II/III were determined at indicated concentrations using HIV-1 Luc-pseudoviruses, EBOV trVLPs, and HIV-1 GFP-pseudoviruses. Levels of viral infections were calculated as relative values, with the DMSO treatment set as 100. The percentage of inhibition was calculated by deduction of the relative viral infection value from 100. Error bars indicate SEMs ( n = 3 biologically independent experiments). One-way ANOVA was applied. ** P < 0.01, *** P < 0.001, ****<0.0001. D Vero-E6 cells were infected with HIV-1 GFP-pseudoviruses expressing EBOV-GP and treated with Tor, Tam, and Tubs I/II/III at indicated concentrations. Infected cells were imaged by EVOS FL Auto Imaging System (scale bar, 200 μm). E The anti-EBOV activity of Tubs I/II/III was titrated in Vero-E6, SNB-19, and Huh-7 cells using HIV-1 Luc-pseudoviruses. The anti-EBOV activity of U18666A (U18) was also titrated in Huh-7 cells similarly. The percentage of inhibition was calculated similarly as aforementioned. F The anti-EBOV activity of Tam, Tor, and Tubs I/II/III was titrated in HEK293T cells using EBOV trVLPs. The percentage of inhibition was calculated similarly as aforementioned. G A summary of IC 50 values on viral infection. H The cytotoxic effect of Tubs I/II/III was titrated in Vero-E6 cells using CellTiter-Glo® Luminescent Cell Viability Assay. Their CC 50 values are shown.

Article Snippet: Goat anti-human ACE2 affinity purified IgG (Cat No. AF933) (1:5000) was from R&D Systems; rabbit anti-human NPC1 (Cat No. ab134113) (1:5000) was from Abcam; rabbit anti-SARS-CoV-spike protein (Cat No. NB100-56047) (1:3000) was from Novus Biologicals; rabbit anti-SARS-CoV-2 spike RBD protein (Cat No. 40592-T62) (1:3000), rabbit anti-Zaire EBOV-GP (Cat No. 40442-T48) (1:5000) were from Sino Biological; mouse monoclonal anti-VSV-G (Cat No. Cat#A02180) (1:2000) was from Abbkine; rat monoclonal anti-FLAG (Cat No. F3165) (1:10,000), horseradish Peroxidase (HRP)-conjugated anti-FLAG (Cat No. A8592) (1:10,000), HRP-conjugated anti-HA (Cat No. H6533) (1:10,000), and HRP-conjugated anti-β-Actin (Cat No. A3854) (1:5000)were from Sigma Aldrich ; HRP-conjugated AffiniPure donkey anti-goat IgG (H + L) (Cat. No. 705-035-003), HRP-conjugated goat anti-mouse IgG (Cat No. 115-035-003) (1:5000) and anti-rabbit IgG (Cat No. 111-035-003) (1:5000), and APC-conjugated polyclonal anti-goat antibody (Cat No. 705-136-147) (1:500) were from Jackson ImmunoResearch.

Techniques: Activity Assay, Infection, Luciferase, Inhibition, Expressing, Imaging, Cell Viability Assay

Journal: Nature Communications

Article Title: Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1

doi: 10.1038/s41467-023-44504-4

Figure Lengend Snippet: A Docking of indicated compounds to NPC1-C and EBOV-GP complex (PDB: 5F1B) was analyzed via Webina. B SNB-19 cells were treated overnight with indicated compounds. After being fixed, cells were stained with filipin (50 µg/mL) and visualized by confocal microscopy (scale bar, 40 μm). Experiments were repeated 3 times independently, and representative results are shown. C Vero-E6 cells were treated with Tubs I/II/III at 0.5 μM and infected with HIV-1 Luc-pseudovirus expressing MARV-GP. Viral infection was determined as previously. D Vero-E6 cells were treated with indicated compounds and infected with HIV-1 Luc-pseudovirus expressing EBOV-GP. Tor, Tam, and Tubs I/II/III were used at 2.5 μM, 5.0 μM, or 0.5 μM, respectively. DMSO was used as a control (Ctr). E Vero-E6 cells were pretreated for 1 h with EIPA and Tubs I/II/III and spinoculated with GFP-labeled EBOV-VLPs expressing EBOV-GP or VSV-G. After removal of VLPs and culture for another 3 h, GFP-positive cells were quantified by flow cytometry. EIPA [5-(N-ethyl-N-isopropyl) amiloride] and Tubs I/II/III were used at 25 μM, or 0.5 μM, respectively. F CTS-B or CTS-L substrates were incubated with cell lysate from A549 cells treated with Tubs I/II/III, and their activity was determined. E-64-d ethyl ester (EST) was used at 10 μM and Tubs I/II/III were used at indicated concentrations. G A549 cells were treated with NH 4 Cl at 100 µM and Tubs I/II/III at 0.5 μM. After being stained with LysoTracker Red, cells were visualized by fluorescence microscope (EVOS FL Auto Imaging System) (scale bar, 200 μm). Experiments were repeated 3 times independently, and representative results are shown. Error bars in C and D indicate SEMs ( n = 3 biologically independent experiments). One-way ANOVA was applied. *** P < 0.001, **** P < 0.0001; n.s. not significant.

Article Snippet: Goat anti-human ACE2 affinity purified IgG (Cat No. AF933) (1:5000) was from R&D Systems; rabbit anti-human NPC1 (Cat No. ab134113) (1:5000) was from Abcam; rabbit anti-SARS-CoV-spike protein (Cat No. NB100-56047) (1:3000) was from Novus Biologicals; rabbit anti-SARS-CoV-2 spike RBD protein (Cat No. 40592-T62) (1:3000), rabbit anti-Zaire EBOV-GP (Cat No. 40442-T48) (1:5000) were from Sino Biological; mouse monoclonal anti-VSV-G (Cat No. Cat#A02180) (1:2000) was from Abbkine; rat monoclonal anti-FLAG (Cat No. F3165) (1:10,000), horseradish Peroxidase (HRP)-conjugated anti-FLAG (Cat No. A8592) (1:10,000), HRP-conjugated anti-HA (Cat No. H6533) (1:10,000), and HRP-conjugated anti-β-Actin (Cat No. A3854) (1:5000)were from Sigma Aldrich ; HRP-conjugated AffiniPure donkey anti-goat IgG (H + L) (Cat. No. 705-035-003), HRP-conjugated goat anti-mouse IgG (Cat No. 115-035-003) (1:5000) and anti-rabbit IgG (Cat No. 111-035-003) (1:5000), and APC-conjugated polyclonal anti-goat antibody (Cat No. 705-136-147) (1:500) were from Jackson ImmunoResearch.

Techniques: Staining, Confocal Microscopy, Infection, Expressing, Labeling, Flow Cytometry, Incubation, Activity Assay, Fluorescence, Microscopy, Imaging

Journal: Nature Communications

Article Title: Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1

doi: 10.1038/s41467-023-44504-4

Figure Lengend Snippet: A Huh-7 cells were treated with SARS2-VLPs and infected with HIV-1 Luc-pseudovirus expressing EBOV-GP. Alternatively, Huh-7-A-T cells were treated with EBOV-VLPs and infected with HIV-1 Luc-pseudovirus expressing SARS2-S. Viral infection is presented as relative values, with the infection in the absence of VLPs set as 100. B Huh-7-A-T cells were infected with HIV-1 Luc-pseudoviruses expressing VSV-G or SARS2-S and treated with indicated compounds at 1 µM. DMSO was used as a control (Ctr). The percentage of inhibition was calculated similarly as aforementioned. C The anti-SARS2 activity of Tubs I/II/III were measured in Huh-7-A-T cells using HIV-1 pseudovirus expressing SARS2-S, and their IC 50 values are indicated. D Huh-7-A-T cells were treated with 1 μM Tubs I/II/III at indicated time points and infected with HIV-1 Luc-pseudovirus expressing SARS2-S. DMSO was used as a control (Ctr). Viral inhibition was determined as previously, E NPC1 was expressed with EBOV-GP, VSV-G, or SARS2-S in HEK293T cells. NPC1 was immunoprecipitated (IP), and proteins in cell lysate (input) and pulldown samples were analyzed by WB. F NPC1 and deletion mutants 1-620 or 1-377 were expressed with EBOV-GP or SARS2-S in HEK293T cells. These NPC1 proteins were immunoprecipitated and proteins were detected by WB. G HIV-1 Luc-pseudoviruses expressing EBOV-GP or SARS2-S were purified by ultracentrifugation. After treatment with thermolysin (TL) at 200 µg/mL, proteins were analyzed by WB. H Recombinant NPC1 proteins were purified by immunoprecipitation from HEK293T cells transfected with a NPC1-expression vector. NPC1 was incubated with purified HIV-1 pseudoviruses expressing EBOV-GP or SARS2-S pre-treated with TL. Proteins associated with NPC1 were pulled down and analyzed by WB. I The anti-SARS2 activity of U18666A (U18) was measured in Huh-7-A-T cells using HIV-1 Luc-pseudovirus expressing SARS2-S. J Purified recombinant NPC1 proteins were incubated with indicated compounds, followed by incubation with HIV-1 pseudoviruses expressing EBOV-GP or SARS2-S after cleavage by TL. Proteins associated with NPC1 were pulled down and analyzed by WB. Experiments in E – J were repeated 3 times independently, and representative results are shown.

Article Snippet: Goat anti-human ACE2 affinity purified IgG (Cat No. AF933) (1:5000) was from R&D Systems; rabbit anti-human NPC1 (Cat No. ab134113) (1:5000) was from Abcam; rabbit anti-SARS-CoV-spike protein (Cat No. NB100-56047) (1:3000) was from Novus Biologicals; rabbit anti-SARS-CoV-2 spike RBD protein (Cat No. 40592-T62) (1:3000), rabbit anti-Zaire EBOV-GP (Cat No. 40442-T48) (1:5000) were from Sino Biological; mouse monoclonal anti-VSV-G (Cat No. Cat#A02180) (1:2000) was from Abbkine; rat monoclonal anti-FLAG (Cat No. F3165) (1:10,000), horseradish Peroxidase (HRP)-conjugated anti-FLAG (Cat No. A8592) (1:10,000), HRP-conjugated anti-HA (Cat No. H6533) (1:10,000), and HRP-conjugated anti-β-Actin (Cat No. A3854) (1:5000)were from Sigma Aldrich ; HRP-conjugated AffiniPure donkey anti-goat IgG (H + L) (Cat. No. 705-035-003), HRP-conjugated goat anti-mouse IgG (Cat No. 115-035-003) (1:5000) and anti-rabbit IgG (Cat No. 111-035-003) (1:5000), and APC-conjugated polyclonal anti-goat antibody (Cat No. 705-136-147) (1:500) were from Jackson ImmunoResearch.

Techniques: Infection, Expressing, Inhibition, Activity Assay, Immunoprecipitation, Purification, Recombinant, Transfection, Plasmid Preparation, Incubation

Journal: Nature Communications

Article Title: Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1

doi: 10.1038/s41467-023-44504-4

Figure Lengend Snippet: A NPC1 was knocked out in indicated cells (see Supplementary Figs. – ). At least one KO clone was obtained from each cell line. The expression of NPC1 and ACE2 in these cells was determined by WB. The ACE2 expression on the cell surface was also determined in A549 WT (−) and WT-A (+) cells by flow cytometry after cells were gated by higher forward scatter (FSC) and side scatter (SSC). Experiments were repeated 3 times independently, and representative results are shown. B Indicated CHO WT and NPC1 -KO cells were infected with HIV-1 Luc-pseudoviruses expressing VSV-G, EBOV-GP, or SARS2-S, and viral infection was determined. C Human NPC1 and its three mutants P691S, L656F, and D786N were expressed in CHO NPC1 -KO cells expressing ACE2 (CHO KO-A). Cells were infected with HIV-1 Luc-pseudoviruses expressing EBOV-GP or SARS2-S, and viral infection was determined. D Indicated A549 cells were infected with HIV-1 Luc-pseudoviruses expressing EBOV-GP or VSV-G, and viral infection was determined. E Indicated A549 cells were transfected with an ACE2- or a TMPRSS2-expression vector and infected with HIV-1 Luc-pseudovirus expressing SARS2-S. Viral infection was determined. F Indicated Caco2 and Vero-E6 cells were infected with HIV-1 Luc-pseudoviruses expressing EBOV-GP, VSV-G, or SARS2-S, and viral infection was determined. G Indicated cell lines were infected with SARS2 authentic viruses. After 24 or 48 h, viral RNA copy numbers were determined by real-time PCR. H HPAE II cells were transfected with indicated siRNAs and infected with SARS2 authentic viruses. NPC1 expression in these cells was detected by WB and viral infection was detected by real-time PCR after 24 or 48 h of infection. I The IC 50 of Tubs I/II/III for authentic SARS2 were measured in Vero-E6 cells. Viral titers were determined by plaque assay after 24 h of infection. PFU, plaque forming units. Error bars in C , E , and F indicate SEMs ( n = 4 biologically independent experiments). One-way ANOVA was applied. *** P < 0.001, **** P < 0.0001.

Article Snippet: Goat anti-human ACE2 affinity purified IgG (Cat No. AF933) (1:5000) was from R&D Systems; rabbit anti-human NPC1 (Cat No. ab134113) (1:5000) was from Abcam; rabbit anti-SARS-CoV-spike protein (Cat No. NB100-56047) (1:3000) was from Novus Biologicals; rabbit anti-SARS-CoV-2 spike RBD protein (Cat No. 40592-T62) (1:3000), rabbit anti-Zaire EBOV-GP (Cat No. 40442-T48) (1:5000) were from Sino Biological; mouse monoclonal anti-VSV-G (Cat No. Cat#A02180) (1:2000) was from Abbkine; rat monoclonal anti-FLAG (Cat No. F3165) (1:10,000), horseradish Peroxidase (HRP)-conjugated anti-FLAG (Cat No. A8592) (1:10,000), HRP-conjugated anti-HA (Cat No. H6533) (1:10,000), and HRP-conjugated anti-β-Actin (Cat No. A3854) (1:5000)were from Sigma Aldrich ; HRP-conjugated AffiniPure donkey anti-goat IgG (H + L) (Cat. No. 705-035-003), HRP-conjugated goat anti-mouse IgG (Cat No. 115-035-003) (1:5000) and anti-rabbit IgG (Cat No. 111-035-003) (1:5000), and APC-conjugated polyclonal anti-goat antibody (Cat No. 705-136-147) (1:500) were from Jackson ImmunoResearch.

Techniques: Expressing, Flow Cytometry, Infection, Transfection, Plasmid Preparation, Real-time Polymerase Chain Reaction, Plaque Assay

Journal: Cell host & microbe

Article Title: Longitudinal human antibody repertoire against complete viral proteome from Ebola virus survivor reveals protective sites for vaccine design

doi: 10.1016/j.chom.2020.01.001

Figure Lengend Snippet: Serial dilutions of serum samples collected at different time points from the EBOV survivor were analyzed for antibody binding to purified proteins from EBOV/Makona strain by SPR. (A-H) Total antibody binding is represented in SPR resonance units (RU) in black for binding to NP (A), VP35 (B). VP40 (B), GP (B). sGP (E), VP30 (F), VP24 (G) and L polymerase (H). Total antibody binding show is calculated RU for an undiluted serum sample. (A-H) Polyclonal antibody affinity maturation to EBOV proteins following EBOV infection in survivor was determined by SPR. Binding affinity of serially diluted post-infection serum to EBOV proteins was measured and is plotted in blue for each of the proteins as mentioned above for total antibody binding. Antibody off-rate constants that describe the fraction of antibody-antigen complexes decaying per second were determined directly from the serum sample interaction with EBOV proteins using SPR in the dissociation phase as described in Materials and Methods. All SPR experiments were performed twice and the researchers performing the assay were blinded to sample identity. The variation for each sample in duplicate SPR runs was <5%. The data shown is average value of two experimental runs. The maximum resonance units (Max RU) data shown was the calculated RU signal for the undiluted serum sample. (I - P) Antibody isotype of EBOV/Makona protein binding antibodies following EBOV infection. The isotype composition of serum antibodies bound to different proteins of EBOV/Makona isolate as measured in SPR. The resonance units for each anti-Makona protein antibody isotype (IgM in black, IgG in green, and IgA in red) was divided by the total resonance units for all antibody isotypes combined to calculate the percentage of each antibody isotype. for individual serum sample.

Article Snippet: Zaire EBOV VP40 Matrix protein , Sino Biologicals , 40446-V07E.

Techniques: Binding Assay, Purification, Infection, Protein Binding

Journal: Cell host & microbe

Article Title: Longitudinal human antibody repertoire against complete viral proteome from Ebola virus survivor reveals protective sites for vaccine design

doi: 10.1016/j.chom.2020.01.001

Figure Lengend Snippet: (A) IgM, IgG and IgA antibody epitope repertoire recognized in the EBOV infected sera at different days post-onset of symptoms ((D7, D13, D19, D31, D110 and D361) and their alignment to the whole proteome of EBOV showing different proteins (NP, VP35, VP40, GP, VP30, VP24 and L). Graphical distribution of representative clones with a frequency of ≥2, obtained after affinity selection, are shown. The horizontal position and the length of the bars indicate the peptide sequence displayed on the selected phage clone to its homologous sequence in the EBOV proteome on alignment. The thickness of each bar represents the frequency of repetitively isolated phage, with the scale shown below the alignment. Scale value for IgM, IgG and IgA is shown enclosed in a red box beneath the respective alignments. The GFPDL affinity selection data was performed in duplicate (two independent experiments by researcher in the lab, who was blinded to sample identity), and similar number of phage clones and epitope repertoire was observed in both phage display analysis. (B) Elucidation of antibody epitope profile against the EBOV proteome following EBOV infection. Antigenic sites within the EBOV proteins recognized by serum antibodies following EBOV infection (based on data presented in Fig. 1A). The amino acid designation is based on the EBOV protein sequence encoded by the complete EBOV/Makona genome. The antigenic regions/sites discovered in this study using the post-infection antibodies are depicted below the EBOV proteome schematic and are color coded. Epitopes of each protein are numbered in a sequential fashion indicated in black and the epitopes are color coded according to the protein color code in the proteome map.

Article Snippet: Zaire EBOV VP40 Matrix protein , Sino Biologicals , 40446-V07E.

Techniques: Infection, Clone Assay, Selection, Sequencing, Isolation

Journal: Cell host & microbe

Article Title: Longitudinal human antibody repertoire against complete viral proteome from Ebola virus survivor reveals protective sites for vaccine design

doi: 10.1016/j.chom.2020.01.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Zaire EBOV VP40 Matrix protein , Sino Biologicals , 40446-V07E.

Techniques: Recombinant